stockrow
Saturday 7 November 2026
Export IMMX’s income statement to Excel — free account
Immix Biopharma, Inc.
IMMX Healthcare Biotechnology
- EPS
- +18.2%
- Free cash flow
- −116.2%
Quarter to June 2026, against a year earlier
8.02
0.82
+11.39%
Follow IMMX
Alert me
Target Price Range
Analyst price targets
Free accountTen years at a glance
| Ten-year view | Analyst estimates Powerpack | |||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Group | Line | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | TTM Jun ’26 | Trend | 10 yrs | 2026e | 2027e | 2028e | Next 3/yr |
| Income, $m | ||||||||||||||||||
| Income, $m | Revenue | — | — | — | — | — | — | — | — | — | — | — | — | 28 | 28 | 99 | +88.3% | |
| Gross margin, % | — | — | — | — | — | — | — | — | — | — | — | — | ||||||
| EBT | — | — | — | (1) | (1) | (24) | (8) | (16) | (22) | (29) | (40) | +77.1% | ||||||
| EBT margin, % | — | — | — | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.0 pt | ||||||
| Net income | — | 0 | — | (1) | (1) | (24) | (8) | (16) | (22) | (29) | (40) | n/m | ||||||
| Per share, $ | ||||||||||||||||||
| Per share, $ | Revenue | — | — | — | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | n/m | |||||
| Earnings | — | — | — | (0.29) | (0.34) | (6.64) | (0.59) | (0.89) | (0.76) | (0.89) | (0.88) | +20.7% | ||||||
| Cash flow | — | — | — | (0.23) | (0.12) | (0.43) | (0.53) | (0.66) | (0.52) | (0.73) | (0.60) | +20.8% | ||||||
| Capex | — | — | — | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | (0.04) | (0.02) | (0.01) | +47.0% | ||||||
| Free cash flow | — | — | — | (0.24) | (0.12) | (0.43) | (0.53) | (0.66) | (0.56) | (0.75) | (0.61) | +21.2% | ||||||
| Book value | — | — | — | (1.08) | (1.40) | 4.90 | 0.95 | 0.93 | 0.47 | 2.85 | 3.59 | n/m | ||||||
| Shares, m | — | — | — | 3 | 3 | 4 | 14 | 17 | 28 | 33 | 46 | +46.2% | ||||||
| Valuation, × | ||||||||||||||||||
| Valuation, × | P/E | — | — | — | — | — | — | — | — | — | — | 0 | — | |||||
| P/S | — | — | — | — | — | — | — | — | — | — | 0 | — | ||||||
| P/B | — | — | — | — | — | — | — | — | — | — | 0 | — | ||||||
| EV/Sales | — | — | — | — | — | — | — | — | — | — | 0 | — | ||||||
| EV/FCF | — | — | — | — | — | — | — | — | — | — | 0 | — | ||||||
| Cash, $m | ||||||||||||||||||
| Cash, $m | Operating cash flow | — | — | — | (1) | 0 | (2) | (7) | (11) | (15) | (24) | (38) | +76.6% | |||||
| Capex | — | — | — | 0 | — | 0 | — | 0 | (1) | (1) | (1) | +115.6% | ||||||
| Free cash flow | — | — | — | (1) | 0 | (2) | (7) | (11) | (16) | (25) | (39) | +77.2% | ||||||
| Balance, $m | ||||||||||||||||||
| Balance, $m | Working capital | — | — | — | (4) | (5) | 18 | 14 | 16 | 12 | 91 | 224 | n/m | |||||
| Net debt | — | — | — | (1) | 4 | (18) | (13) | (18) | (18) | (100) | (232) | +127.0% | ||||||
| Shareholders’ equity | — | — | — | (4) | (5) | 18 | 13 | 16 | 13 | 94 | 229 | n/m | ||||||
| Returns, % | ||||||||||||||||||
| Returns, % | ROA | — | — | — | (206.34) | (154.86) | (260.35) | (49.73) | (88.57) | (100.82) | (46.07) | (31.34) | +160.3 pt | |||||
| ROIC | — | — | — | 0.00 | 0.00 | (244.50) | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.0 pt | ||||||
| ROE | — | — | — | 0.00 | 27.41 | (367.80) | (52.84) | (105.07) | (146.76) | (55.00) | (34.18) | (55.0) pt | ||||||
| People | ||||||||||||||||||
| People | Employees | — | — | — | — | 2 | 2 | 11 | 17 | 21 | 21 | — | +60.0% | |||||
| Revenue/emp, $m | — | — | — | — | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | — | n/m | ||||||
Negative figures in brackets.
estimates
Fundamentals updated 26 Oct 2026
Immix Biopharma, Inc. vs peers in Biotechnology (Q) = latest quarter vs a year earlier
| Company | Market cap | P/E | Fwd P/E | Revenue growth (Q) | EPS growth (Q) | FCF growth (Q) | Gross margin (Q) | EBIT margin (Q) | Compare |
|---|---|---|---|---|---|---|---|---|---|
| HELP Cybin Inc. | $613.0M | — (loss-making) | — (loss-making) | — | n/m | −25.60% (below 0%: shrinking) | 0.00% | 0.00% | Compare |
| GERN Geron Corporation | $610.4M | — (loss-making) | — (loss-making) | +27.45% (above 0%: growing) | n/m | +176.13% (above 0%: growing) | 89.95% | 9.63% | Compare |
| DSGN Design Therapeutics, Inc. | $605.2M | — (loss-making) | — (loss-making) | — | n/m | −7.00% (below 0%: shrinking) | 0.00% | 0.00% | Compare |
| KURA Kura Oncology, Inc. | $604.9M | — (loss-making) | — (loss-making) | +36.54% (above 0%: growing) | n/m | −109.05% (below 0%: shrinking) | 98.84% | (349.77%) | Compare |
| AVBP ArriVent BioPharma, Inc. | $603.0M | — (loss-making) | — | — | n/m | −51.51% (below 0%: shrinking) | — | 0.00% | Compare |
| IMMX Immix Biopharma, Inc. | $596.9M | — (loss-making) | — | — | n/m | −116.22% (below 0%: shrinking) | — | 0.00% | |
| OBX Obsidian Therapeutics, Inc | $593.0M | — | — | — | n/m | — | — | 0.00% | Compare |
| OLMA Olema Pharmaceuticals, Inc. | $591.5M | — (loss-making) | — | — | n/m | −54.33% (below 0%: shrinking) | 0.00% | 0.00% | Compare |
| APMD Apnimed, Inc. | $589.5M | 0.8× | 4.6× | — | — | — | 89.98% | (96.89%) | Compare |
| Median of peers | $604.0M | — | — | — | — | −38.55% | 44.98% | 0.00% |
Pay and ownership Proxy statement filed 6 April 2026
Ownership
Directors and executive officers, together
30.30%
Yekaterina Chudnovsky
9.50%
Jason Hsu
9.40%
Janus Henderson Group PLC
7.40%
Saturn V Capital Management LP
7.00%
Millennium Management LLC
5.30%
Ownership is the proxy’s own table: the directors and officers as a group, and every holder of 5% or more.
Read the proxy statement